Health plan pharmacy director: considerations for treatment and management of RSV disease

Area of Science:

• Pediatrics
• Public Health
• Health Economics

Background:

• Respiratory Syncytial Virus (RSV) immunoprophylaxis, specifically palivizumab, offers proven protection for high-risk infants against severe RSV infection and associated morbidity.
• Managed Care Organizations (MCOs) face significant annual costs associated with RSV immunoprophylaxis, presenting a financial challenge.
• The high cost of palivizumab necessitates a careful evaluation of its use within MCO frameworks.

Purpose of the Study:

• To explore the challenges MCOs face in providing RSV immunoprophylaxis.
• To identify the need for standardized guidelines for RSV management.
• To determine how consensus on guidelines can facilitate affordable treatment for at-risk infants.

Main Methods:

• This study is a conceptual analysis and review of existing literature on RSV immunoprophylaxis and MCO cost-effectiveness.
• It synthesizes perspectives from MCOs, healthcare providers, and professional medical organizations.
• The analysis focuses on the economic and clinical implications of palivizumab use.

Main Results:

• RSV immunoprophylaxis with palivizumab is effective but expensive, posing a significant financial burden on MCOs.
• Lack of uniform guidelines contributes to the challenge of cost management for RSV prevention.
• Agreement on common guidelines is crucial for ensuring access to necessary treatments for vulnerable infants.

Conclusions:

• Establishing consensus-based guidelines for RSV immunoprophylaxis is essential for MCOs.
• Standardized management protocols can help MCOs balance the cost of palivizumab with the need for infant protection.
• Collaborative efforts among stakeholders can lead to more affordable and accessible RSV prevention strategies for high-risk populations.